Biophytis forms a Scientific Advisory Board for its phase 2 OBA clinical study on obesity.

Biophytis, a clinical-stage biotech firm focused on age-related diseases, has announced the formation of a new Scientific Advisory Board (SAB) to support its phase 2 OBA clinical study on obesity. The SAB comprises global obesity medical experts, including Prof. Dennis Villareal from the US and Prof. Francisco Guarner from Spain. The OBA SAB aims to guide Biophytis in developing its BIO101 (20-hydroxyecdysone) for obesity treatment, in combination with GLP1-RA, and contribute to the finalization of the OBA Phase 2 clinical study design. Biophytis plans to file for an Investigational New Drug (IND) application to initiate the OBA Phase 2 clinical study.

Articles

PR-inside

Finanz Nachrichten

LeLézard

Street Insider

Market Screener

Salt Lake City Sun

Tennessee Daily

-- show less --

Further Reading

Related Stories